Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 1/20 | 0.68 |
| ▸ | RXRA | P19793 | 2/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | HMGCR | P04035 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27936537 | 0.88 | PRKAA2 (0.76) | PRKAA2RXRANR1I2NR4A2PDE4D | |
| SCHEMBL14163464 | 0.83 | PRKAA2 (0.72) | PRKAA2RXRANR1I2NR4A2PDE4D | |
| SCHEMBL356302 | 0.82 | PRKAA2 (0.61) | PRKAA2RXRANR1I2NR4A2PDE4D | |
| SCHEMBL30060873 | 0.81 | PRKAA2 (1.00) | PRKAA2RXRANR1I2NR4A2PDE4D | |
| SCHEMBL14749820 | 0.81 | PRKAA2 (0.77) | PRKAA2RXRANR1I2NR4A2PDE4D | |
| SCHEMBL31546 | 0.81 | PRKAA2 (1.00) | PRKAA2RXRANR1I2NR4A2PDE4D | |
| SCHEMBL27947390 | 0.81 | PRKAA2 (0.72) | PRKAA2RXRANR1I2NR4A2PDE4D | |
| SCHEMBL27947387 | 0.80 | PRKAA2 (0.60) | PRKAA2RXRANR1I2NR4A2PDE4D | |
| SCHEMBL24454 | 0.79 | PRKAA2 (0.77) | PRKAA2RXRANR1I2NR4A2PDE4D | |
| SCHEMBL3709827 | 0.79 | PRKAA2 (0.77) | PRKAA2RXRANR1I2NR4A2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120016129-A1 | Process for Preparing Pitavastatin, Intermediates and Pharmaceuctically Acceptable Salts Thereof | MSN LABORATORIES LIMITED (IN) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016129-A1 | Process for Preparing Pitavastatin, Intermediates and Pharmaceuctically Acceptable Salts Thereof | PCSK9, HMGCR, HDLBP | PRKAA2 679/4885RXRA 695/4885NR1I2 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.